PatientView recently published their 2018 annual survey "The Corporate Reputation of Pharma”. Based on feedback from 1,500 patient groups, 46 pharma companies were surveyed for their corporate reputation based on 12 different indicators. Lundbeck continues to be top tier among patient groups who have worked with us, despite a drop in the overall ranking. Specifically, we excelled in the Net Promoter Score that measures patient groups' loyalty to Lundbeck.
Read the release from PatientView.
“I am extremely proud that we continue to be rated number one in the rankings given to companies by patient groups who state that they have done work with the company. Not only that, the overall number of patient groups who would recommend Lundbeck has risen to 72% vs 60% last year. Collaboration with patient groups is pivotal in our work and strong partnerships are key in our commitment to restore brain health,” says Deborah Dunsire, President & CEO, Lundbeck.
Patient groups' loyalty to Lundbeck is best in class
Again this year PatientView assessed the patient groups’ loyalty to the companies, measured by the Net Promoter Score, which is a score for how likely patient groups are to recommend a company. Lundbeck excelled on this parameter and came out best in class with the highest Net Promoter Score among the 46 pharma companies.
The total number of patient groups across all therapy areas included in the PatientView study increased in 2018. Overall, Lundbeck ranked 12th vs 7th last year among patient groups knowing the company, and on familiarity we ranked 9th vs 2nd last year among patient groups that have worked with us.
|In 2018, the twelve indicators of corporate reputation were:
|1. Patient centricity
||5i. Transparency: pricing
||7. Quality of relationships
|2. Patient information
||5ii. Transparency: clinical-trial data
||8. Services 'beyond the pill'
|3. Patient safety
||5iii. Transparency: external stakeholders
||9i. R&D: research
|4. High-quality products
||9ii. R&D: development